Big Pharma
2 May 2024 AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in second wave of challenges by Federal Trade Commission | ‘Junk patents’ block competition and ramp up prices unfairly, says FTC chair.
25 April 2024
16 April 2024
Latest Features
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.
Big Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis.
Asia
A Korean district court has applied a landmark ruling in a complicated vaccine dispute involving Pfizer, explain Young Kim, Yu-Seog WON, In Hwan Kim, and Amy Oh of Kim & Chang.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Americas
In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.
Big Pharma
A Federal Circuit decision provides lessons on why inaction over patent terms may risk incurable invalidation of important patents, writes Vincent Shier of Haynes Boone.
Big Pharma
Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents.
More News
11 April 2024 Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro.
9 April 2024 Delaware district court more convinced by Arbutus on claim construction points | Canadian biotech “pleased” with outcome in latest round of dispute over lipid nanoparticles delivery system.
9 April 2024 Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion |
Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan.
4 April 2024 Senior pharma attorney and LSPN Boston speaker delves into emerging tech and patent law, the importance of communication and awareness, and the challenge of enablement | Advice on effective management of IP portfolios in the life sciences sector.
21 March 2024 US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.
21 March 2024 Pharma giant says defendant initially concealed new role at competitor | Employee allegedly took “vast amounts” of confidential information and accessed it while employed by Pfizer.
19 March 2024 ViQual Medical Technology had accused Kaiser Foundation Health Plan of stealing secrets related to monitors for diabetes and other conditions | California judge says no evidence confidential information was taken or used.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox